Neoplasms

3,817 trials 1,526 recruiting

Filter these 3,817 trials by phase, country and sponsor.

Open in Search →

A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab i… Ended

2023-506948-17-00 Previously Untreated Chronic Lymphocytic Leukemia 5 2024-04-05
An Open-label Dosimetry, Tolerability and Safety Study of lutetium (177Lu) vipivotide tetraxetan in Patients with Progressive PSMA-Positive … Ended

2023-503925-20-00 Progressive PSMA-Positive Metastatic Castration-Resista 4 2024-04-04
A Phase 1 first-in-human study evaluating safety, pharmacokinetics and efficacy of ABBV-706 as monotherapy and in combination with budigalim… Ended

2023-504598-18-00 Advanced solid tumors 1 2024-04-03
Study with Various Immunotherapy Treatments in Participants With Lung Cancer Ended

2022-502916-35-01 Advanced Non-Small Cell Lung Cancer 4 2024-03-27
Tiragolumab and atezolizumab associated with chemotherapy in triple negative breast cancer Ended

2022-501561-51-00 Early and metastatic triple negative breast cancer 4 2024-03-27
Randomized open-label Phase 2 trial evaluating the impact of enhanced versus standard dermatologic management on selected dermatologic adver… Ended

2023-505863-35-00 EGFR-mutated Advanced or Metastatic Non-small Cell Lung 4 2024-03-20
A multicentre, Phase II, single-arm, interventional study of neoadjuvant durvalumab and platinum-based chemotherapy (CT), followed by either… Ended

2023-503357-35-00 Non-small Cell Lung Cancer (NSCLC) 4 2024-03-20
A phase I, open-label, multi-center study of KFA115 as a single agent and in combination with pembrolizumab in patients with select advanced… Ended

2022-502381-25-01 Thymic Carcinoma 1 2024-03-15
MK-2870 in Post Platinum and Post Immunotherapy Endometrial Cancer Ended

2023-504816-14-00 Endometrial cancer 5 2024-03-08
A study of continued treatment with regorafenib in participants with solid tumors who have participated in other Bayer studies Ended

2023-507084-19-00 Solid malignant tumors 4 2024-03-07
Study which tests 3 medicines (SB27, EU sourced Keytruda, and US sourced Keytruda) in early or locally advanced non-small cell lung cancer p… Ended

2023-507438-25-00 Non-small cell lung cancer 2 2024-02-28
A Phase 3 Randomized Study Comparing Talquetamab in Combination with Pomalidomide (Tal-P), Talquetamab in Combination with Teclistamab (Tal-… Ended

2022-502446-27-00 Relapsed or Refractory Myeloma 5 2024-02-26
Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants with Treatment Naïve Mantle Cell Lymphoma Ended

2023-505205-16-00 Treatment Naïve Mantle Cell Lymphoma 4 2024-02-21
A first-in-human study to learn about how safe BAY 3375968 is, how it moves into, through, and out of the body, and to find its best dose wh… Ended

2023-505594-32-00 Advanced solid tumors 1 2024-02-20
Patient Preference for Route of Administration with Intravenous Infusion Switch to Subcutaneous I-O Regimens in Melanoma Ended

2023-504515-33-00 Melanoma 4 2024-02-19
Study which tests 2 medications (SB27, Keytruda) to compare how effective, safe and well tolerated in a large number of metastatic non-squam… Ended

2023-507448-36-00 Non-small Cell Lung Cancer 5 2024-02-16
A study of sigvotatug vedotin versus docetaxel in previously treated non-small cell lung cancer (Be6A Lung-01) Ended

2023-503827-25-01 Non-Small Cell Lung Cancer (NSCLC) 5 2024-02-16
Patient Preference Study of SC Pembrolizumab versus IV Pembrolizumab with hyaluronidase (MK-3475A) in multiple cancer types Ended

2023-506017-22-00 Melanoma, Renal Cell Carcinoma, Non-small cell lung can 4 2024-02-16
A phase Ib dose finding study assessing safety and activity of [177Lu]Lu-NeoB in combination with ribociclib and fulvestrant in participants… Ended

2022-502465-18-00 Advanced or metastatic breast cancer 9 2024-02-15
A phase 1 study of JNJ-86974680, an A2a receptor antagonist, administered as monotherapy and in combination with cetrelimab and radiotherapy… Ended

2023-506393-12-00 Advanced non-small cell lung cancer 1 2024-02-13
An international prospective open-label, multi-center, randomized, non-comparative phase II study of lutetium [177Lu] vipivotide tetraxetan … Ended

2022-503040-41-00 PSMA PET scan positive Castration-Resistant Prostate Ca 4 2024-02-09
NeoAdjuvant Dynamic marker - Adjusted Personalized Therapy comparing trastuzumab-deruxtecan versus pacli-/docetaxel+carboplatin+trastuzumab+… Ended

2024-514458-61-01 HER2+ early breast cancer 4 2024-02-05
Study of HRO761 alone or in combination in cancer patients with specific DNA alterations called Microsatellite Instability-High or Mismatch … Ended

2022-502314-93-00 MSIhi or dMMR advanced unresectable or metastatic solid 1 2024-02-05
ELACESTRANT in Women and Men with CDK4/6 Inhibitor-Naive Estrogen Receptor Positive, HER-2 Negative Metastatic Breast Cancer: An Open-Label … Ended

2023-503214-68-00 metastatic breast cancer 4 2024-01-31